Cerevel.com

Site Inspections

Overview & More informations

Cerevel Therapeutics (Nasdaq: CERE) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders. The company's lead product candidate, CVL-882, is a selective inhibitor of the alpha 7 nicotinic acetylcholine receptor (nAChR) being developed for the treatment of schizophrenia, other CNS disorders, and substance use disorders. In May 2021, Cerevel announced positive top-line results from a Phase 2 trial of CVL-882 for schizophrenia. The trial met its primary endpoint, showing a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score in patients treated with CVL-882 compared to placebo. Cerevel is also developing other product candidates for the treatment of CNS disorders, including CVL-231, a selective inhibitor of the TrkB receptor being developed for the treatment of depression, and CVL-983, a selective inhibitor of the EphB2 receptor being developed for the treatment of Alzheimer's disease.

Cerevel was founded in 2013 and is headquartered in Boston, Massachusetts. The company has a team of experienced scientists and executives with a track record of success in developing and commercializingCNS therapies. Cerevel has raised over $500 million in funding from a syndicate of investors including Flagship Pioneering, Google Ventures, and Fidelity Investments.

According to data from SimilarWeb, cerevel.com receives approximately 10,000 monthly visits from unique visitors. The website is most popular in the United States, followed by the United Kingdom and Canada. The website's content is primarily focused on providing information about Cerevel's products and pipeline, as well as the company's mission and values.

Cerevel is a publicly traded company on the Nasdaq stock exchange under the ticker symbol CERE. The company's stock price has been relatively volatile since its initial public offering in 2018, but it has generally trended upwards over the past year.

Overall, Cerevel is a promising clinical-stage biopharmaceutical company with a focus on developing treatments for CNS disorders. The company's lead product candidate, CVL-882, has shown promising results in clinical trials, and the company has a number of other product candidates in development. Cerevel is well-funded and has a team of experienced scientists and executives, which positions the company well for continued success in the future.

Domains Expiration Date Updated